Tags

Type your tag names separated by a space and hit enter

Emerging target-based paradigms to prevent and treat migraine.
Clin Pharmacol Ther 2013; 93(1):78-85CP

Abstract

Migraine is a primary brain disorder resulting from altered modulation of normal sensory stimuli and trigeminal nerve dysfunction. The second edition of the International Classification of Headache Disorders (ICHD-2) defines seven subtypes of migraine. Migraine treatment can be acute or preventive. New targeted therapies include 5-HT(1F) receptor agonists, calcitonin gene-related peptide (CGRP) antagonists, nitric oxide synthetase inhibitors, and ion channel antagonists. A recent development is the creation of antibodies to CGRP and its receptor for migraine prevention.

Authors+Show Affiliations

Jefferson Headache Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA. stephen.silberstein@jefferson.edu

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

23212108

Citation

Silberstein, S D.. "Emerging Target-based Paradigms to Prevent and Treat Migraine." Clinical Pharmacology and Therapeutics, vol. 93, no. 1, 2013, pp. 78-85.
Silberstein SD. Emerging target-based paradigms to prevent and treat migraine. Clin Pharmacol Ther. 2013;93(1):78-85.
Silberstein, S. D. (2013). Emerging target-based paradigms to prevent and treat migraine. Clinical Pharmacology and Therapeutics, 93(1), pp. 78-85. doi:10.1038/clpt.2012.198.
Silberstein SD. Emerging Target-based Paradigms to Prevent and Treat Migraine. Clin Pharmacol Ther. 2013;93(1):78-85. PubMed PMID: 23212108.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Emerging target-based paradigms to prevent and treat migraine. A1 - Silberstein,S D, Y1 - 2012/12/05/ PY - 2012/12/6/entrez PY - 2012/12/6/pubmed PY - 2013/2/9/medline SP - 78 EP - 85 JF - Clinical pharmacology and therapeutics JO - Clin. Pharmacol. Ther. VL - 93 IS - 1 N2 - Migraine is a primary brain disorder resulting from altered modulation of normal sensory stimuli and trigeminal nerve dysfunction. The second edition of the International Classification of Headache Disorders (ICHD-2) defines seven subtypes of migraine. Migraine treatment can be acute or preventive. New targeted therapies include 5-HT(1F) receptor agonists, calcitonin gene-related peptide (CGRP) antagonists, nitric oxide synthetase inhibitors, and ion channel antagonists. A recent development is the creation of antibodies to CGRP and its receptor for migraine prevention. SN - 1532-6535 UR - https://www.unboundmedicine.com/medline/citation/23212108/Emerging_target_based_paradigms_to_prevent_and_treat_migraine_ L2 - https://doi.org/10.1038/clpt.2012.198 DB - PRIME DP - Unbound Medicine ER -